These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 22609113)

  • 41. Dual delivery of biological therapeutics for multimodal and synergistic cancer therapies.
    Jang B; Kwon H; Katila P; Lee SJ; Lee H
    Adv Drug Deliv Rev; 2016 Mar; 98():113-33. PubMed ID: 26654747
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Supramolecular Delivery Systems for Non-Platinum Metal-Based Anticancer Drugs.
    Ringhieri P; Morelli G; Accardo A
    Crit Rev Ther Drug Carrier Syst; 2017; 34(2):149-183. PubMed ID: 28605318
    [TBL] [Abstract][Full Text] [Related]  

  • 43. CNIO cancer conference: targeted search for anticancer drugs.
    Fischer PM
    Expert Opin Investig Drugs; 2003 Jun; 12(6):1039-44. PubMed ID: 12783608
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Elucidation of the Mechanism of Action for Metal Based Anticancer Drugs by Mass Spectrometry-Based Quantitative Proteomics.
    Jia S; Wang R; Wu K; Jiang H; Du Z
    Molecules; 2019 Feb; 24(3):. PubMed ID: 30736320
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Metallodrugs in cancer nanomedicine.
    Peña Q; Wang A; Zaremba O; Shi Y; Scheeren HW; Metselaar JM; Kiessling F; Pallares RM; Wuttke S; Lammers T
    Chem Soc Rev; 2022 Apr; 51(7):2544-2582. PubMed ID: 35262108
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Anticancer metallodrug research analytically painting the "omics" picture--current developments and future trends.
    Groessl M; Hartinger CG
    Anal Bioanal Chem; 2013 Feb; 405(6):1791-808. PubMed ID: 23070042
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Peptide-mediated vectorization of metal complexes: conjugation strategies and biomedical applications.
    Soler M; Feliu L; Planas M; Ribas X; Costas M
    Dalton Trans; 2016 Aug; 45(33):12970-82. PubMed ID: 27095089
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Frontiers of metal-coordinating drug design.
    Palermo G; Spinello A; Saha A; Magistrato A
    Expert Opin Drug Discov; 2021 May; 16(5):497-511. PubMed ID: 33874825
    [No Abstract]   [Full Text] [Related]  

  • 49. An omics perspective to the molecular mechanisms of anticancer metallo-drugs in the computational microscope era.
    Spinello A; Magistrato A
    Expert Opin Drug Discov; 2017 Aug; 12(8):813-825. PubMed ID: 28604114
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The Application of Prodrug-based Drug Delivery Strategy in Anticancer Drugs.
    Liu N; Chen Q; Zhang Q; Wang J; Si R; Zhang J; Pan X
    Curr Top Med Chem; 2021; 21(24):2184-2204. PubMed ID: 34503405
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Take-home message: are we "off target"?
    Khurdayan VK
    Drug News Perspect; 2007 Jun; 20(5):345-51. PubMed ID: 17878963
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Therapeutic peptides for chemotherapy: Trends and challenges for advanced delivery systems.
    Ilangala AB; Lechanteur A; Fillet M; Piel G
    Eur J Pharm Biopharm; 2021 Oct; 167():140-158. PubMed ID: 34311093
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Metallodrugs as Anticancer Chemotherapeutics and Diagnostic Agents: A Critical Patent Review (2010-2020).
    Fotopoulou E; Titilas I; Ronconi L
    Recent Pat Anticancer Drug Discov; 2022; 17(1):42-54. PubMed ID: 34493191
    [TBL] [Abstract][Full Text] [Related]  

  • 54. How Computational Chemistry and Drug Delivery Techniques Can Support the Development of New Anticancer Drugs.
    Garofalo M; Grazioso G; Cavalli A; Sgrignani J
    Molecules; 2020 Apr; 25(7):. PubMed ID: 32290224
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Advanced LC-analysis of human plasma for metallodrug metabolites.
    Sooriyaarachchi M; Morris TT; Gailer J
    Drug Discov Today Technol; 2015 Sep; 16():24-30. PubMed ID: 26547418
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Chirality in metal-based anticancer agents.
    Wang Y; Huang H; Zhang Q; Zhang P
    Dalton Trans; 2018 Mar; 47(12):4017-4026. PubMed ID: 29479608
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Stimuli-Responsive Metal Complexes for Biomedical Applications.
    Amarsy I; Papot S; Gasser G
    Angew Chem Int Ed Engl; 2022 Oct; 61(40):e202205900. PubMed ID: 35781763
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A review on the recent advances of interaction studies of anticancer metal-based drugs with therapeutic targets, DNA and RNAs.
    Khan HY; Ansari MF; Tabassum S; Arjmand F
    Drug Discov Today; 2024 Jul; 29(7):104055. PubMed ID: 38852835
    [TBL] [Abstract][Full Text] [Related]  

  • 59. N-Acylhydrazones as drugs.
    Thota S; Rodrigues DA; Pinheiro PSM; Lima LM; Fraga CAM; Barreiro EJ
    Bioorg Med Chem Lett; 2018 Sep; 28(17):2797-2806. PubMed ID: 30006065
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Bioanalytical strategies to evaluate cisplatin nanodelivery systems: From synthesis to incorporation in individual cells and biological response.
    Gutierrez-Romero L; Díez P; Montes-Bayón M
    J Pharm Biomed Anal; 2024 Jan; 237():115760. PubMed ID: 37839264
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.